November 2024 - Page 2 of 2 - BioMedWire (BMW)

TuesdayNov 12, 2024 9:30 am

Kairos Pharma Ltd. (NYSE American: KAPA) Is ‘One to Watch’

Kairos Pharma’s partnership with Cedars-Sinai Medical Center enhances clinical trial efficiency and accelerates the development of new therapeutic solutions. The company holds a robust intellectual property portfolio with patents extending through 2040, providing a strong competitive advantage in the oncology market. ENV105, Kairos’s lead drug candidate, shows promise in reversing drug resistance in prostate and lung cancers, addressing key markets with high demand for novel treatments. Positioned in high-growth oncology segments, Kairos Pharma meets substantial market needs, driven by the increasing global incidence of drug-resistant cancers. The company’s focus on biomarker development improves patient targeting, enhancing therapy success rates and…

FridayNov 08, 2024 10:00 am

New Graphene Chip Could Revolutionize Brain Cancer Treatment

Researchers have developed a chip that may revolutionize how brain cancer is treated. This revolutionary device is made of graphene, a material made of pure carbon that’s over a hundred times stronger than steel. Graphene is extracted from graphite and was invented two decades ago by Konstantin Novoselov and Andre Geim. Novoselov and Geim, both Manchester University researchers, won the 2010 Nobel Prize in physics for their work. The flexible chip is the size of a postage stamp and has been dubbed the brain-computer interface device. It was designed to identify cancer cells based on their electrical emissions, which differ…

ThursdayNov 07, 2024 10:00 am

European Commission Imposes Hefty Fine on Firm for Blocking Rival MS Drug Developer

Last week, the European Commission announced that it had imposed a half-a-billion dollar fine on Teva, a multinational pharmaceutical firm based in Israel. The company, which specializes in generic drugs, is said to have artificially extended patent protection for its multiple sclerosis drug known as Copaxone. The drug has glatiramer acetate as its active ingredient. In a statement, the commission argued that the company’s actions may have hindered considerable savings by nations across Europe given that other versions of the medication may be cheaper than Copaxone. In total, Teva is expected to pay a 462.6 million euro fine. This is…

TuesdayNov 05, 2024 10:00 am

Changes Coming to Medicare Advantage and Medicare Part D Next Year

Medicare is focused on helping older individuals, particularly those aged 65 and above, to access health care services at affordable costs. Keeping up to date with the insurance plan’s elements makes it easier to familiarize oneself with the changes happening annually and gauge whether they still align with one’s needs. Below, we examine some of the changes coming to both Medicare Part D and Medicare Advantage in 2025. New payment option for Medicare Part D As from January 2025, seniors using this health insurance plan will be afforded the option to sign up for a drug payment plan. Instead of…

TuesdayNov 05, 2024 8:00 am

Annovis Bio Inc. (NYSE: ANVS) Highlights Buntanetap Results at 17th Clinical Trials on Alzheimer’s Disease (‘CTAD’) 2024 Conference

Two posters were presented by Annovis’ President and CEO, Dr. Maria Maccecchini, focusing on the company’s lead drug candidate buntanetap and its performance in clinical trials for the treatment of Alzheimer’s disease (“AD”). A leading event for the Alzheimer’s research community, CTAD 2024, brought together key members of pharmaceutical companies, academic research centers, and patient advocacy groups to discuss avenues for AD treatment. Buntanetap has been shown to significantly improve cognition in early AD patients, both ApoE4 carriers and non-carriers, and normalize biomarkers associated with AD pathology. The company is preparing for Phase 3 clinical trials for buntanetap in early-stage…

FridayNov 01, 2024 10:00 am

Study Explores How Antimicrobials Impact the Risk of Developing Parkinson’s Disease

A new study has investigated how exposure to antimicrobials influences the risk of Parkinson's disease development. Parkinson’s disease is a brain disorder that affects an individual’s movement, causing stiffness, tremors as well as issues with coordination and balance. The condition’s symptoms worsen as it progresses. In advanced stages, patients may find it hard to talk and walk. Parkinson’s has no cure and affects more than 8.5 million individuals globally. Projections expect that by 2040, more than 12 million individuals will be living with the disorder. Genetic and environmental factors are said to contribute to the condition’s etiology, with researchers theorizing…